Valsartan
Valsartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for Diovan tablets (valsartan), lists three uses: treating high blood pressure in adults and children 1 year and older, reducing hospitalization for heart failure (NYHA class II-IV) in adults, and reducing cardiovascular deaths in clinically stable adults with left ventricular failure or dysfunction after a myocardial infarction. Diovan is the brand name on the label read.
Also called Diovan
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 69749; UNII 80M03YXJ7I. UNII 80M03YXJ7I is the UNII of the substance as the label names it. MeSH descriptor D000068756 is Valsartan. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Novartis Pharmaceuticals Corporation label for Diovan (valsartan) tablets, application NDA021283, effective 2026-08-11 in openFDA; Drugs@FDA lists the application's sponsor as NOVARTIS. Other valsartan labels, the Diovan HCT combination label and fixed-dose combination labels with other substances were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 24 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 24
- Phase 3 or 4
- 21
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Enrolling by invitation | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 2 | 0 | 1 | 3 |
| Phase 3 | 1 | 1 | 8 | 1 | 1 | 12 |
| Phase 4 | 0 | 0 | 7 | 0 | 2 | 9 |
| All phases | 1 | 1 | 17 | 1 | 4 | 24 |
Conditions these trials study
- Hypertension (high blood pressure)
- Heart failure
- Cardiomyopathy (heart muscle disease)
- Chronic kidney disease (CKD)
- Heart attack (myocardial infarction)
- Heart failure with mildly reduced or preserved ejection fraction
- ST-elevation heart attack (STEMI)
- Diabetes mellitus
- Heart valve disease
- Hypertrophic cardiomyopathy
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context Adults for whom the US label of valsartan (Diovan) lists an indication: hypertension, NYHA class II-IV heart failure, left ventricular failure or dysfunction after myocardial infarction
- Recipient
- Adult
- Population
- Adult patients described in the indications section of the label. The hypertension sentence also names children, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passages read state
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Adult patients with hypertension
- Adult patients with heart failure (NYHA class II-IV)
- Clinically stable adult patients with left ventricular failure or left ventricular dysfunction following myocardial infarction
- Excluded
- None stated
The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults; and for the reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or left ventricular dysfunction following myocardial infarction.
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-08-11
- Source state
- Current
- Version fingerprint
688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260811.
- Retrieved
- Source effective date
- 2026-08-11
- Source state
- Current
- Version fingerprint
688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
Background openFDA Drugs@FDA record for application NDA021283 (DIOVAN, sponsor NOVARTIS): product and sponsor
- Locator
- results[0].products[0].brand_name
- How it applies
- Drugs@FDA product listing for application NDA021283, which confirms the product the label belongs to.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
a78049a0e3c8f2cb62336a0d03a25f1f483fb5af1df4497ffbd39f3710ee44ee- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short values are quoted. The raw record is committed in the atlas repository.
Context Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older
- Recipient
- Child
- Population
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Label wording: children 1 year and older
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Children with hypertension (children 1 year and older)
- Excluded
- None stated
The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure, in children 1 year and older.
Applies to Child Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-08-11
- Source state
- Current
- Version fingerprint
688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260811.
- Retrieved
- Source effective date
- 2026-08-11
- Source state
- Current
- Version fingerprint
688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure, in children 1 year and older.
Applies to Child Children for whom the US label of valsartan (Diovan) lists hypertension as an indication: children 1 year and older
Population, setting and follow-up
- Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Label wording: children 1 year and older
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that names children in the hypertension indication, quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-08-11
- Source state
- Current
- Version fingerprint
688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260811.
- Retrieved
- Source effective date
- 2026-08-11
- Source state
- Current
- Version fingerprint
688d5ee8e5f2f1cff69717113df109a07a3c5a1071f65e97b1df46fb12f5314d- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.
BYVALSON
No label from the application holder was found in the openFDA label dataset for application NDA206302. This page does not show another labeler's label in its place.
DIOVAN
No label from the application holder was found in the openFDA label dataset for application NDA020665. This page does not show another labeler's label in its place.
DIOVAN
No label from the application holder was found in the openFDA label dataset for application NDA021283. This page does not show another labeler's label in its place.
DIOVAN HCT
No label from the application holder was found in the openFDA label dataset for application NDA020818. This page does not show another labeler's label in its place.
ENTRESTO SPRINKLE
- Application
- NDA218591
- Labeler
- Novartis Pharmaceuticals Corporation
- Label version
- Version 25, effective
- Label set id
000dc81d-ab91-450c-8eae-8eb74e72296f- Boxed warning
- Yes: WARNING: FETAL TOXICITY
- Sections the label has
- Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies
EXFORGE
No label from the application holder was found in the openFDA label dataset for application NDA021990. This page does not show another labeler's label in its place.
EXFORGE HCT
No label from the application holder was found in the openFDA label dataset for application NDA022314. This page does not show another labeler's label in its place.
PREXXARTAN
No label from the application holder was found in the openFDA label dataset for application NDA209139. This page does not show another labeler's label in its place.
VALTURNA
No label from the application holder was found in the openFDA label dataset for application NDA022217. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
- Approval
NDA020665 - Approval
NDA020818 - Approval
NDA021283 - Supplemental approval
NDA021283 - Supplemental approval
NDA020665 - Supplemental approval
NDA021283 - Supplemental approval
NDA020818 - Supplemental approval
NDA021283 - Supplemental approval
NDA020818 - Approval
NDA021990 - Supplemental approval
NDA021283 - Supplemental approval
NDA021990 - Supplemental approval
NDA020818 - Approval
NDA022314 - Approval
NDA022217 - Approval
NDA206302 - Approval
NDA209139 - Supplemental approval
NDA021283 - Approval
NDA218591
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists hypertension as an indication: Hypertension (high blood pressure)
The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults; and for the reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or left ventricular dysfunction following myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists NYHA class II to IV heart failure, to reduce hospitalization for heart failure in adults, as an indication: Heart failure
The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults; and for the reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or left ventricular dysfunction following myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists reduction of cardiovascular mortality after myocardial infarction in clinically stable adults with left ventricular failure or dysfunction as an indication: Heart attack (myocardial infarction)
The US label of Diovan (valsartan) tablets, in the Novartis Pharmaceuticals Corporation version dated 2026-08-11 in openFDA, lists the medicine for hypertension, to lower blood pressure in adults (the same label sentence also names children, recorded separately); for heart failure (NYHA class II-IV), to reduce hospitalization for heart failure in adults; and for the reduction of cardiovascular mortality in clinically stable adults with left ventricular failure or left ventricular dysfunction following myocardial infarction.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 9
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 5 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 24
Record details
- Record id
cardio:valsartan- Content hash
fe2b710435b27ded9faa8be25db3ebef6b5fdbf8145db28011671a152b3fa124